Atomic force microscopy detection of serological markers of viral hepatites B and C

被引：5

作者：

Ivanov Yu.D. ^{[1
]}

Frantsuzov P.A. ^{[1
]}

Pleshakova T.O. ^{[1
]}

Ziborov V.S. ^{[2
]}

Svetlov S.K. ^{[1
]}

Krohin N.V. ^{[1
]}

Konev V.A. ^{[1
]}

Kovalev O.B. ^{[1
]}

Uchaikin V.F. ^{[1
]}

Yastrebova O.N. ^{[3
]}

Sveshnikov P.G. ^{[4
]}

Archakov A.I. ^{[1
]}

机构：

[1] Institute of Biomedical Chemistry, Russian Academy of Medical Sciences, Moscow 119121

[2] Scientific Association for High Temperatures, Russian Academy of Sciences, Moscow

[3] JSV vECTOR-BEST, Novosibirsk

[4] Russian Research Center of Molecular Diagnostics and Therapy, Moscow

来源：

Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry | 2010年 / 4卷 / 2期

基金：

俄罗斯基础研究基金会;

关键词：

atomic-force microscopy; hepatitis B virus surface antigen (HBsAg); hepatitis C virus core antigen (HCVcoreAg);

D O I：

10.1134/S1990750810020010

中图分类号：

学科分类号：

摘要：

The possibility of detection of serological markers, containing the hepatitis B surface antigen (HBsAg) and hepatitis C virus core-antigen (HCVcoreAg) in human serum, by a new atomic force microscopy (AFM)-based nanotechnological approach has been demonstrated. The antibodies against the hepatitis B virus surface antigen (anti-HBsAg) and the antibodies against the hepatitis C virus core antigen (anti-HCVcoreAg) were immobilized on an AFM-chip. It was shown that such approach enables to detect HBsAg, HCVcoreAg and the viral fragments containing these antigens in the serum. The comparative analysis of detection of HBsAg- and HCVcoreAg-containing particles by the AFM method versus traditional methods (ELISA, PCR) has demonstrated the 75% coincidence of results between the AFM and two other methods. © 2010 Pleiades Publishing, Ltd.

引用

页码：117 / 122

页数：5

共 20 条

[1]

Farci P., Alter H.J., Miller R.H., Shih J.W., Jett B., Purcell R.H., J. Med. Virol., 37, pp. 210-214, (1991)

[2]

Baranov A.A., Kaganov B.S., Et al., Diagnostika i Lechenie Khronicheskikh Gepatitov B, C, i D U Detei (Diagnostics and Treatment of Viral Hepatites B, C, and D in Children), Moscow, 2003

[3]

Archakov A.I., Ivanov Y.D., Lisitsa A.V., Zgoda V.G., Proteomics, 7, pp. 4-9, (2007)

[4]

Anderson N.L., Anderson N.G., Molecular and Cellular Proteomics, 1, pp. 845-867, (2002)

[5]

Sabatino L., Chopra I.J., Tanavoli S., Iacconi P., Iervasi G., Thyroid., 11, pp. 733-739, (2001)

[6]

Ivanov Yu.D., Kanaeva I.P., Eldarov M.A., Skryabin K.G., Lehnerer M., Schulze J., Hlavica P., Archakov A.I., Biochem. Mol. Biol. Int., 42, pp. 731-737, (1997)

[7]

Ivanov Yu.D., Kanaeva I.P., Kuznetsov V.Yu., Lehnere M., Schulze J., Hlavica P., Archakov A.I., Arch. Biochem. Biophys., 362, pp. 87-93, (1999)

[8]

Ivanov Yu.D., Usanov S.A., Archakov A.I., Biochem. Mol. Biol. Int., 47, pp. 327-336, (1999)

[9]

Ivanov Yu.D., Kanaeva I.P., Archakov A.I., Biochem.Biophys. Res. Commun., 273, pp. 750-752, (2000)

[10]

Ivanov Yu.D., Gnedenko O.V., Konev V.A., Kovalev O.B., Nikolaeva L.I., Semenova N.V., Uchaikin V.F., Archakov A.I., Vopr. Med. Khim., 47, pp. 419-425, (2001)

← 1 2 →